CD3-CD56+ NK cells display an inflammatory profile in RR-MS patients
Immunology Letters, cilt.216, ss.63-69, 2019 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 216
- Basım Tarihi: 2019
- Doi Numarası: 10.1016/j.imlet.2019.10.006
- Dergi Adı: Immunology Letters
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.63-69
- Anahtar Kelimeler: IL-22, Multiple sclerosis, Natural killer cells, NKG2A, NKG2D, NKp44
- İstanbul Medipol Üniversitesi Adresli: Hayır
Özet
Multiple Sclerosis (MS) is an immune-mediated and neurodegenerative disease of central nervous system. Relapsing-remitting (RR)-MS occurring with acute attacks and remissions, is the most common clinical type of MS. There are different strategies applied in first-line treatment of RR-MS patients such as interferon-beta (IFN-β) and glatiramer acetate. In this study, activating and inhibitory receptor expressions and interleukin (IL)-22 levels of NK cells were investigated in RR-MS patients with or without IFN-β therapy. Activating receptor expression and IL-22 levels of NK cells were increased in RR-MS patients under IFN-β therapy. Elevated NK cells with activating profile and increased IL-22 under IFN-β therapy suggest that IFN-β treatment might direct NK cells toward a pro-inflammatory status.